Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study

Diabetes Res Clin Pract. 2011 Jul;93(1):123-30. doi: 10.1016/j.diabres.2011.05.004. Epub 2011 May 31.

Abstract

Objective: To analyze the prescribing patterns of antidiabetic and cardiovascular medications among diabetics in the most highly populated Italian Region, from 2000 to 2008.

Methods: Data were obtained from the Lombardy Region administrative health databases. The standardized prevalence of antidiabetic and cardiovascular drugs use was calculated within each study year. The prescription trends of initial treatment with antidiabetic drugs were also analyzed.

Results: From 2000 to 2008 there was an increase in the proportion of patients treated with biguanides (from 53.4% to 66.5%; p<0.0001) while those receiving sulfonylurea decreased (from 78.6% to 56.4%; p<0.0001). A sharp increase of metformin (as monotherapy) as initial treatment was also observed (from 15.2% to 48.8%; p<0.0001). The percentage of patients receiving renin-angiotensin system inhibitors, lipid-lowering drugs and antiplatelets increased between 2000 and 2008, from respectively 45.1% to 63.3%, 13.6% to 43.2% and 21.6% to 40.9 (p<0.0001). Multivariate analyses indicated that changes in prescriptions were statistically significant for both antidiabetic and cardiovascular drugs.

Conclusion: This study documents progressive changes in the prescription of antidiabetic and cardiovascular drugs in accordance with guidelines. However, the use of metformin as first line therapy was still suboptimal and cardiovascular preventive strategies were only partially implemented in community practice.

MeSH terms

  • Diabetes Mellitus / drug therapy*
  • Drug Prescriptions / statistics & numerical data*
  • Drug Utilization / statistics & numerical data*
  • Drug Utilization / trends*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Hypolipidemic Agents / therapeutic use
  • Italy
  • Metformin / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Sulfonylurea Compounds / therapeutic use

Substances

  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Platelet Aggregation Inhibitors
  • Sulfonylurea Compounds
  • Metformin